Literature DB >> 282940

Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and response to therapy.

Y M Rustum, H D Preisler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 282940

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  32 in total

1.  Cellular pharmacology of 1-beta-D-arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells.

Authors:  R L Momparler; N Onetto-Pothier; D Y Bouffard; L F Momparler
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  Clinical pharmacokinetics-pharmacodynamics of anticancer drugs.

Authors:  W E Evans; M V Relling
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

Review 3.  Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.

Authors:  W Hiddemann
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

4.  Synthesis and tumour-localizing properties of [18F]-5-fluorocytosine-arabinoside and [18F]-5-fluorocyclocytidine.

Authors:  G W Visser; O Zwaagstra; G C Gorree; P Moonen; J D Herscheid; A Hoekstra
Journal:  Eur J Nucl Med       Date:  1986

5.  Quantitation of synergism of arabinosylcytosine and cladribine against the growth of arabinosylcytosine-resistant human lymphoid cells.

Authors:  Tieran Han; Marilyn Fernandez; Ting-Chao Chou; Ram P Agarwal
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

Review 6.  Selective uptake and retention of anticancer agents by sensitive cells.

Authors:  D L Hill; J A Montgomery
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

7.  Enhanced retention of cytosine arabinoside and its metabolites and synergistic cytotoxicity by sequential treatment with dipyridamole in L5178Y leukemia.

Authors:  J L Yang; J C White; R L Capizzi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cells.

Authors:  Henry Ogbomo; Martin Michaelis; Denise Klassert; Hans Wilhelm Doerr; Jindrich Cinatl
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

Review 9.  Pharmacokinetic optimisation of anticancer therapy.

Authors:  J Liliemark; C Peterson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

10.  Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside.

Authors:  H D Preisler; Y M Rustum; N Azarnia; R Priore
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.